Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Metrics to compare | SPRC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.2x | 39.9x | −0.5x | |
PEG Ratio | −0.52 | 0.00 | 0.00 | |
Price/Book | −12.6x | 1.1x | 2.6x | |
Price / LTM Sales | 81.7x | 1.6x | 3.3x | |
Upside (Analyst Target) | - | 17.8% | 47.0% | |
Fair Value Upside | Unlock | −3.5% | 5.7% | Unlock |